Theremia
AI-driven molecule design for pharma.
Theremia applies AI-powered simulations to optimize small-molecule derivatives for efficacy across patient groups. Pharmaceutical developers use its platform to identify improved variants before clinical testing—reducing safety risks and extending drug patent life without additional trials.
Founders
Iris Maréchal
CEO
Iris is a former BCG consultant who has worked with some of the world’s leading pharma companies. As a student, she founded a nonprofit to national scale.
Chloé Geoffroy
Cofounder
Chloé is a Pharmacist and Chemical Engineer with a PhD and post-doc from École Normale Supérieure in Neuropharmacology.